Published in final edited form as:

Curr Rheumatol Rep. 2010 February ; 12(1): 34–39. doi:10.1007/s11926-009-0081-6.

The Current State of Biomarkers in Systemic Sclerosis

Laura K. Hummers

Division of Rheumatology, Johns Hopkins Scleroderma Center, Johns Hopkins University, 5501 Hopkins Bayview Circle, Room 1B.7, Baltimore, MD 21224, USA

Laura K. Hummers: lhummers@jhmi.edu

Abstract

Scleroderma is a complex, multisystem autoimmune rheumatic disease with wide heterogeneity in phenotype and outcome. There are often coexisting ongoing pathologic processes including immune system activation, progressive fibrosis, and vascular disease in subsets of patients. Currently, it is challenging to identify patients at risk for developing adverse outcomes and to determine which patients are responding to current therapies. For these reasons, it is highly valuable to find easily measurable biomarkers that may represent ongoing disease activity or treatment response. This review examines the current state of biomarker development in systemic sclerosis and identifies areas in which further work should be directed.

Keywords

Scleroderma; Biomarkers; Fibrosis; Pulmonary hypertension

Introduction

When confronted with a newly diagnosed patient with systemic sclerosis, clinicians must determine who may develop early progressive fibrosis and who is at risk for future pulmonary arterial hypertension (PAH). The early clinical features of the disease may provide some guidance. A patient with edematous skin, new development of Raynaud phenomenon, and antibodies to topoisomerase-I has a higher likelihood of having more skin and lung fibrosis early in the disease course. This may be helpful in initial risk stratification, but even this type of fine-tuned phenotyping is not specific enough to be the sole basis of treatment decisions. In those patients who we elect to treat, our current response measures are not particularly sensitive to change in the interval that is most clinically relevant. Determining which patients will develop the progressive vasculopathy that characterizes PAH and ischemic digital ulcerations, or the more abrupt vascular insult of renal crisis, is also fundamentally important. Autoantibody specificity may offer some value in specific situations (RNA polymerase I/III in determining risk of renal crisis), but lacks sufficient sensitivity and specificity (roughly half of renal crisis patients do not produce this antibody and only 30% to 40% of antibody-positive patients develop renal crisis) [1]. The ability to better risk stratify patients is one of the key potential uses of biomarkers. An ideal biomarker measures pathways fundamental to disease pathogenesis, predicts future development of relevant outcomes, is easily measurable, and changes with effective therapy. At present, no measures fulfill these criteria, but areas exist in which progress has been made. In addition,

Correspondence to: Laura K. Hummers, lhummers@jhmi.edu.

Disclosure No potential conflict of interest relevant to this article was reported.

multiple novel therapies are being investigated that may provide an ideal setting for investigating potential markers.

The list of possible uses of biomarkers in scleroderma is long. The disease is difficult to objectively measure and aspects of the disease may change slowly with time or may smolder. Several areas, however, likely have the most urgency and the highest likelihood for discovery of a tenable biomarker. These areas include assessment of activity in the skin or lung in patients with early disease, and determination of the risk for development of clinically significant vascular events (PAH, digital ulcers, renal crisis) and intermediate end points for clinical trials that examine mechanisms of the drug or relevant biologic pathways.

Assessing Disease Activity and Risk for Progressive Skin and Lung Disease

The earliest features of scleroderma are inflammatory in nature. Early scleroderma skin disease is edematous, with histopathologic analysis revealing dermal inflammation and patients with lung involvement demonstrating a mixed inflammatory infiltrate by cytopathology. This process is thought to precede activation of fibroblasts, which may then sustain fibrosis independently. Therefore, multiple cellular pathways may be exploited to yield a measurable marker. In terms of clinical measurements that may assess activity, there are nonspecific markers of inflammation such as erythrocyte sedimentation rate and C-reactive protein (CRP). Some of these nonspecific markers have been incorporated into disease activity measures (eg, Valentini disease activity index) that have some validity [2]. These nonspecific markers have not been shown to predict outcome and are independent of any direct measurement of mechanism, but they could be modifiable by therapy.

Profibrotic cytokines, such as transforming growth factor β (TGF- β) and connective tissue growth factor (CTGF), are clearly abnormal in scleroderma and involve abnormal tissue expression, implicating them in disease progression. As such, they may be relevant therapeutic targets. CTGF levels (or its cleavage products) have consistently been found to be elevated in the peripheral blood in scleroderma, correlate with skin and lung fibrosis, and are higher in earlier disease, implicating a role in the development or early progression of the fibrotic phenotype [3,4]. In other fibrosing diseases (eg, diabetic nephropathy), CTGF levels may be predictive of outcome, but longitudinal studies in scleroderma have not been performed. TGF- β levels have inconsistently been found to be abnormal in scleroderma serum, potentially reflecting either measurements of different disease phase or perhaps more likely that there is sequestration of the molecule in affected sites [5]. An interesting new avenue of investigation is the measurement of TGF- β -responsive gene signature in the skin biopsies of scleroderma patients [6•]. These data also suggest that this signature is expressed more strongly in patients with more extensive skin and lung disease. This type of approach may lead to further mechanistic approaches to therapy and may possibly be usable as intermediate biologic end points in early-phase clinical trials [7].

Markers of collagen turnover have been examined in cross-sectional study and in some clinical trials [8]. The most commonly studied markers of collagen turnover include serum N-terminal pro-peptide of type I (PINP) and type III (PIIINP) collagen; C-terminal pro-peptide of type I collagen; cross-linked carboxyterminal telopeptide of type I collagen; and C-terminal telopeptide of type I collagen. Of these, PIIINP has been the most thoroughly investigated in the past 20 years. Studies have suggested elevated levels in the serum of scleroderma patients and some correlation with degree of skin involvement lung involvement and to some extent disease progression [9–12]. The use of immunosuppressant therapy has been associated with a decrease in PIIINP levels [13]. Markers of collagen synthesis have been investigated in a placebo-controlled study of the CAT-192, an anti-

TGF- β monoclonal antibody. In this study, PINP correlated with changes in modified Rodnan skin score. However, levels of PIIINP did not. Another study, however, suggested that levels of PIIINP decreased in an open-label study of 16 patients treated with infliximab, but skin scores did not improve in this 26-week trial. A systematic review of available data in 12 cross-sectional studies examining serum markers of collagen turnover was performed in 2004 by Dziadzio et al. [14]. This study demonstrated wide heterogeneity in methodology, clinical data reporting, and small sample sizes [14]. The authors conclude, however, that longitudinal study should still be pursued as the limitations of the prior studies did not preclude the potential utility of these markers.

Bronchoalveolar lavage fluid measurement of neutrophilia and eosinophilia had been demonstrated in retrospective studies to correlate with a high risk of progressive decline in lung function [15], but this association did not hold when data from the Scleroderma Lung Study (SLS) were evaluated [16]. Several serum glycoproteins have been examined as potential markers of progressive lung involvement in scleroderma. They are both produced by type 2 alveolar epithelial cells. Increased levels have correlated with higher risk for interstitial lung disease (ILD) progression in scleroderma and may diminish with cyclophosphamide therapy [17]. Evaluation of samples from subjects screened or enrolled in the SLS study demonstrated the serum levels of both surfactant protein D (SP-D) and KL-6 correlated with “alveolitis” (defined by bronchoalveolar lavage [BAL] or high-resolution CT per the SLS protocol) and extent of CT fibrosis and, to some extent, lung function parameters [18•]. This study found SP-D to be fairly sensitive (89%) and KL-6 to be specific (90%) as markers of “alveolitis.” This study could not assess response to therapy because of the limited number of samples. More recently, several chemokines, including Chemokine (C-C motif) ligand 18 (CCL18), Chemokine (C-C motif) ligand 2 (CCL2) and chemokine (C-X-C motif) ligand 10 (CXCL10) have been evaluated as markers of lung disease in scleroderma. Gene expression profiles from BAL fluid showed increased expression of chemokines and chemokine receptor genes [19]. Serum levels of CCL18 are associated with the presence of ILD in patients with scleroderma and possibly correlated with active lung disease more closely than KL-6 and SP-D, although the number of patients in this study was small [20]. When concurrently examined in serum and in cultured cells from BAL supernatants, CCL18 was noted to be increased in those with lower lung function and BAL neutrophilia/eosinophilia, and an increase in CCL18 positive alveolar macrophages was noted by flow cytometry [21]. CCL2 was examined in a large sample of scleroderma patients and noted to be elevated in some patients with both limited and diffuse scleroderma and in the diffuse patients the elevations were associated with early disease but not with pulmonary vascular disease [22•].

Prediction of Risk and Progression of Vascular Disease

Although the development and progression of fibrotic skin and lung disease is typically a concern at disease onset, the major clinically relevant vascular events, such as the development of clinically evident pulmonary hypertension occur years into the disease. In general, less is known about clinical risk factors that predict pulmonary hypertension development. For example, the autoantibody associations are not as strong, likely reflecting the heterogeneous cascade of events that may lead to pulmonary vascular disease (hypoxia from ILD, primary pulmonary vasculopathy, direct myocardial insult), and some antibodies that associate with the phenotype are not widely commercially available [23]. Strong circumstantial evidence also exists of a long preclinical disease state; it is widely recognized that the diffusing capacity of the lung for carbon monoxide (DLCO) drops perhaps years before clinical onset of disease [24]. This is an ideal situation for the development of a biomarker that could be used for risk stratification purposes, with potential ability to speed the diagnosis, intensify screening or diagnostic algorithms, or even change disease course by

instituting therapy at a less advanced state [25]. A problem, however, is that the biology of the process is extremely complex, involving perturbations of multiple cell types and biologic pathways. In addition, many of the markers have pleiotropic effects, may either reflect ongoing insult or accumulated damage, or may not be specific to the clinical phenotype of interest (ie, the relationship to pulmonary vascular disease is confounded by an association with peripheral vascular disease). These problems, however, are not insurmountable if measurements are taken from large cohorts of prospectively followed, well-characterized patients. To date, most of the investigations of biomarkers in vascular disease in scleroderma come from relatively small cross-sectional studies, with variable attention to clinical phenotype.

Clinical Markers

DLCO

Several investigations have examined the predictive capability for the DLCO for the development of clinically significant pulmonary vascular disease. It has long been recognized that diminished DLCO is a poor prognostic indicator [26,27]. In addition, it has been noted that DLCO is severely depressed years before a patient develops clinically recognized isolated PAH [24]. In a prospective evaluation of 384 patients with complete data collection and no pulmonary hypertension at baseline, 18 patients developed pulmonary vascular disease over a median follow-up time of 41 months (8 patients with PAH, 8 patients with pulmonary venous hypertension, and 2 patients associated with severe ILD) [28]. In this study, those with incident PAH had a significantly lower DLCO than those with no PH at baseline (54% vs 73% predicted; $P=0.02$). In another single-center cohort study of 101 scleroderma patients, the eight patients who developed PAH during 28 months of follow-up, had a significantly lower DLCO (58% vs 80% predicted; $P=0.002$) and a DLCO/alveolar volume (VA) less than 70% predicted carried an HR of 18.8 (95% CI, 1.7–206.8) for development of PAH in multivariate analysis and DLCO/VA less than 60% predicted an HR of 36.7 (95% CI, 3.45–387.6) [29•]. By receiver operating characteristic analysis, the sensitivity and specificity of a DLCO/VA less than 70% predicted were 87.5% and 79.5%, respectively, and a DLCO/VA less than 60% were 62.5% and 88.1%, respectively.

Brain Natriuretic Peptide

Brian natriuretic peptide and its N-terminal prohormone are secreted by ventricular myocytes in response to stretch, hypoxia, and by certain neurohormonal stimuli. Among scleroderma patients, these hormones correlate with hemo-dynamic, echocardiographic, and functional measurements of pulmonary vascular disease [30]. Levels of N-terminal prohormone brain natriuretic peptide (NT-proBNP) are disproportionately higher in patients with scleroderma-associated PAH compared with idiopathic PAH and also associate with higher risk of mortality [31,32]. It is thought to have an extremely high negative predictive value for diagnosis of PAH [32]. Allanore et al. [29•] also explored NT-proBNP in a prospective cohort of scleroderma subjects followed for incident development of PAH. This study found that NT-proBNP levels, at a threshold of more than 97% manufacturer-provided normal levels carries a significant HR for the future development of PAH, which is enhanced by measures of DLCO. Measurement of BNP may likely enhance our ability to diagnose early pulmonary vascular disease, and as such may prove to be quite a useful adjunct to current screening methodologies. It is not known, however, if levels measured at an even earlier stage that still fall within typical levels of normal may still have some predictive value, as is the case with high-sensitivity CRP and coronary artery disease. Also, because the measure is not specific to the right ventricle, this marker may have low specificity to PAH, as patients may have pulmonary venous hypertension or other cardiac dysfunction.

Endothelial Markers

Endothelial insult may be the earliest pathologic feature in scleroderma [33]. Damage to the endothelium itself or the downstream effects in the surrounding tissues may lead to a host of consequences leading to end-organ damage. Measures of endothelial cell damage, such as von Wille-brand factor (vWF), in cross-sectional studies, consistently find elevated levels [34], although correlation with clinical evidence of vascular disease is not clear [35,36]. Endothelin-1 is a potent vasoconstrictor secreted from multiple cell types including the endothelium and is over-expressed in the vessels of scleroderma tissues [37]. Elevation of endothelin-1 in the plasma of scleroderma patients is widely reported [38], but a clear association with vascular phenotypes in scleroderma is lacking. Given the suggested role of endothelin-1 in the pathogenesis of pulmonary vascular disease and potential role in inducing fibrosis, it may still be a molecule with potential as a biomarker for scleroderma possibly for vascular or even fibrotic disease [39]. However, given that levels seem to be elevated in broad populations of scleroderma patients, it may lack sufficient specificity to one process (eg, PAH) and may not be discriminating enough as a predictive tool.

Adhesion molecule expression is induced by endothelial cell damage and this, in turn, may lead to further damage by allowing the transmigration of inflammatory cells. Increases in a number of circulating adhesion molecules (soluble intercellular adhesion molecule-1 [sICAM-1]; soluble vascular adhesion molecule 1 [sVCAM-1]; E-selectin) have been seen in scleroderma patients with some association with some vascular phenotypes [40]. One small study noted that levels of VCAM-1, ICAM-1, and vWF were elevated in patients with scleroderma and PAH (and scleroderma without PAH), but levels of the adhesion molecules (not vWF) diminished to within normal range in those with PAH treated with bosentan [36].

Angiogenic Markers

There is substantial evidence for imbalanced angiogenesis as a contributing factor for scleroderma vascular disease. Plasma from scleroderma patients is associated with a decrease in endothelial tube formation in in vitro assays [41•]. Circulating factors influencing local tissue angiogenesis include growth factors and inhibitors of angiogenesis such as endostatin and angiostatin. Studies of the peripheral blood of scleroderma patients demonstrate abnormalities in angiogenic factors including growth factors (vascular endothelial growth factor [VEGF], fibroblast growth factors, placental growth factor, platelet-derived growth factor, and hepatocyte growth factor [HGF]), metalloproteinases, and angiostatic molecules (endostatin, thrombospondin, angiostatin, soluble endoglin).

Despite clear clinical evidence of a diminution of new blood vessel growth in scleroderma, some potent angiogenic growth factors are consistently elevated. VEGF is the most widely studied. Although some studies suggest that elevated levels of VEGF correlate with phenotype, a correlation with vascular events is not as clear [42,43]. It has been suggested that initially, VEGF may be of benefit in reducing damage to small blood vessels, but chronic overexpression may even be deleterious [42,44]. This may be combined with an overproduction of angiostatic molecules including soluble VEGF receptors, endostatin, angiostatin, and soluble endoglin. Endostatin is a potent inhibitor of angiogenesis and levels are increased in the scleroderma group compared with control patients and may correlate with pulmonary and peripheral vascular disease [43,45]. Soluble endoglin has been noted to be elevated in several studies and a more clear association with vascular phenotypes is noted [46•,47]. The soluble VEGF receptors and soluble endoglin are of particular interest given their predictive ability in other disease states such as preeclampsia [48]. An imbalance of the regulators of angiogenesis with an increase in circulating inhibitors and a decrease in some growth factors such as HGF could lead to imbalanced vascular repair mechanisms and

prevent the normal responses of ischemic injury. Although these studies all point to potential mechanisms of how defects in angiogenesis may play a role in the marked vascular abnormalities seen in scleroderma, none of these factors have been evaluated in a group of patients prospectively to assess their potential as predictors of outcome in severe vascular events.

Prediction of Response to Therapy

There are two important aspects of biomarkers that are assessed as part of a clinical trial. There are markers that assess if the agent being studied has had its intended biological effect and markers that may be used as intermediate end points for a desired clinical outcome. Ideally, one marker would fulfill both roles. Clinical trials are an ideal setting for examining potential biomarkers. A typical clinical trial in scleroderma selects groups of patients that are relatively homogeneous, manifest a particular component of scleroderma (early active skin, active lung, digital ulcerations) and have longitudinal follow-up and sample collection. It is vital that biomarker development be included in the planning of all future clinical trials in scleroderma and that data and samples from completed clinical trials be used for this purpose.

Conclusions

The development and validation of biomarkers in scleroderma may help to improve the risk stratification of patients at onset, target screening to higher risk subsets, select patients who may have improved response to therapy, determine who is responding to therapy at an earlier stage, and potentially lead to new therapeutic targets. Assessments of biomarkers must occur in large cohorts of patients with specific attention to fine clinical phenotyping and ideally with longitudinal data focusing on selected outcomes. Attention in biomarker development should focus on their discriminatory value for specific clinical features and outcomes within scleroderma, rather than searching for those markers that are uniformly and strikingly different compared with control populations. In addition, it is vital that biomarker development strategies be incorporated into the development planning for all clinical trials.

Acknowledgments

This work is supported by National Institute of Arthritis and Musculoskeletal and Skin Diseases/National Institutes of Health grant K23 AR052742.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as:

• Of importance

•• Of major Importance

1. Penn H, Howie AJ, Kingdon EJ, et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. *QJM*. 2007; 100:485–494. [PubMed: 17601770]
2. Valentini G, Bencivelli W, Bombardieri S, et al. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. *Ann Rheum Dis*. 2003; 62:901–903. [PubMed: 12922968]
3. Dziadzio M, Usinger W, Leask A, et al. N-terminal connective tissue growth factor is a marker of the fibrotic phenotype in scleroderma. *QJM*. 2005; 98:485–492. [PubMed: 15955800]
4. Sato S, Nagaoka T, Hasegawa M, et al. Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. *J Rheumatol*. 2000; 27:149–154. [PubMed: 10648031]

5. Dziadzio M, Smith RE, Abraham DJ, et al. Circulating levels of active transforming growth factor beta1 are reduced in diffuse cutaneous systemic sclerosis and correlate inversely with the modified Rodnan skin score. *Rheumatology (Oxford)*. 2005; 44:1518–1524. [PubMed: 16159952]
- 6••. Sargent JL, Milano A, Bhattacharyya S, et al. A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. *J Invest Dermatol*. 2009 Oct 8. (Epub ahead of print). This study used data from in vitro studies of scleroderma fibroblasts to develop a mechanistically derived gene expression profile. This TGF-β responsive gene signature from skin biopsies correlated with the diffuse subset of scleroderma and with more significant skin and lung disease.
7. Chung L, Fiorentino DF, Benbarak MJ, et al. Molecular framework for response to imatinib mesylate in systemic sclerosis. *Arthritis Rheum*. 2009; 60:584–591. [PubMed: 19180499]
8. Denton CP, Merkel PA, Furst DE, et al. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. *Arthritis Rheum*. 2007; 56:323–333. [PubMed: 17195236]
9. Krieg T, Perlish JS, Fleischmajer R, Braun-Falco O. Collagen synthesis in scleroderma: selection of fibroblast populations during subcultures. *Arch Dermatol Res*. 1985; 277:373–376. [PubMed: 4026379]
10. Black CM, McWhirter A, Harrison NK, et al. Serum type III procollagen peptide concentrations in systemic sclerosis and Raynaud's phenomenon: relationship to disease activity and duration. *Br J Rheumatol*. 1989; 28:98–103. [PubMed: 2706431]
11. Diot E, Diot P, Valat C, et al. Predictive value of serum III procollagen for diagnosis of pulmonary involvement in patients with scleroderma. *Eur Respir J*. 1995; 8:1559–1565. [PubMed: 8575585]
12. Scheja A, Wildt M, Wollheim FA, et al. Circulating collagen metabolites in systemic sclerosis. Differences between limited and diffuse form and relationship with pulmonary involvement. *Rheumatology (Oxford)*. 2000; 39:1110–1113. [PubMed: 11035131]
13. Heickendorff L, Zachariae H, Bjerring P, et al. The use of serologic markers for collagen synthesis and degradation in systemic sclerosis. *J Am Acad Dermatol*. 1995; 32:584–588. [PubMed: 7896946]
14. Dziadzio M, Smith RE, Abraham DJ, et al. Serological assessment of type I collagen burden in scleroderma spectrum disorders: a systematic review. *Clin Exp Rheumatol*. 2004; 22:356–367. [PubMed: 15144134]
15. White B, Moore WC, Wigley FM, et al. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. *Ann Intern Med*. 2000; 132:947–954. [PubMed: 10858177]
16. Strange C, Bolster MB, Roth MD, et al. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. *Am J Respir Crit Care Med*. 2008; 177:91–98. [PubMed: 17901414]
17. Yanaba K, Hasegawa M, Takehara K, Sato S. Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis. *J Rheumatol*. 2004; 31:1112–1120. [PubMed: 15170923]
- 18•. Hant FN, Ludwicka-Bradley A, Wang HJ, et al. Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma. *J Rheumatol*. 2009; 36:773–780. In this study, serum collected from patients in the Scleroderma Lung Study was examined for these two glycoproteins that are secreted by pneumocytes. Researchers showed clear correlations of these markers with clinical measures of active lung disease in scleroderma including CT evidence of ground glass, BAL fluid cytology, and pulmonary function. [PubMed: 19286849]
19. Luzina IG, Atamas SP, Wise R, et al. Gene expression in bronchoalveolar lavage cells from scleroderma patients. *Am J Respir Cell Mol Biol*. 2002; 26:549–557. [PubMed: 11970906]
20. Kodera M, Hasegawa M, Komura K, et al. Serum pulmonary and activation-regulated chemokine/CCL18 in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis. *Arthritis Rheum*. 2005; 52:2889–2896. [PubMed: 16142750]

21. Prasse A, Pechkovsky DV, Toews GB, et al. CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis. *Arthritis Rheum.* 2007; 56:1685–1693. [PubMed: 17469163]
22. Carulli MT, Handler C, Coghlan JG, et al. Can CCL2 serum levels be used in risk stratification or to monitor treatment response in systemic sclerosis? *Ann Rheum Dis.* 2008; 67:105–109. In this large cross-sectional study, the chemokine CCL2 was noted to be elevated in scleroderma and levels correlated with fibrotic disease features. This marker is notable for having clear variability with phenotype being higher in those with earlier, active disease. [PubMed: 17604287]
23. Steen VD. Autoantibodies in systemic sclerosis. *Semin Arthritis Rheum.* 2005; 35:35–42. [PubMed: 16084222]
24. Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. *Arthritis Rheum.* 2003; 48:516–522. [PubMed: 12571862]
25. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. *Clin Pharmacol Ther.* 2001; 69:89–95. [PubMed: 11240971]
26. Peters-Golden M, Wise RA, Hochberg MC, et al. Carbon monoxide diffusing capacity as predictor of outcome in systemic sclerosis. *Am J Med.* 1984; 77:1027–1034. [PubMed: 6507456]
27. Morgan C, Knight C, Lunt M, et al. Predictors of end stage lung disease in a cohort of patients with scleroderma. *Ann Rheum Dis.* 2003; 62:146–150. [PubMed: 12525384]
28. Hachulla E, de Groote P, Gressin V, et al. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. *Arthritis Rheum.* 2009; 60:1831–1839. [PubMed: 19479881]
29. Allanore Y, Borderie D, Avouac J, et al. High N-terminal probrain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. *Arthritis Rheum.* 2008; 58:284–291. This is the first study to examine biomarkers to predict the development of pulmonary vascular disease in a prospective cohort study. Elevated levels of NT-proBNP predicted development of pulmonary vascular disease in this cohort. [PubMed: 18163505]
30. Dimitroulas T, Giannakoulas G, Karvounis H, et al. Natriuretic peptides in systemic sclerosis-related pulmonary arterial hypertension. *Semin Arthritis Rheum.* 2009 Jun 16. (Epub ahead of print).
31. Mathai SC, Hassoun PM. N-terminal brain natriuretic peptide in scleroderma-associated pulmonary arterial hypertension. *Eur Heart J.* 2007; 28:140–141. author reply 141. [PubMed: 17164254]
32. Williams MH, Handler CE, Akram R, et al. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. *Eur Heart J.* 2006; 27:1485–1494. [PubMed: 16682379]
33. Sgonc R, Gruschwitz MS, Dietrich H, et al. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. *J Clin Invest.* 1996; 98:785–792. [PubMed: 8698871]
34. Herrick AL, Illingworth K, Blann A, et al. Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. *Ann Rheum Dis.* 1996; 55:122–127. [PubMed: 8712862]
35. Hesselstrand R, Ekman R, Eskilsson J, et al. Screening for pulmonary hypertension in systemic sclerosis: the longitudinal development of tricuspid gradient in 227 consecutive patients, 1992–2001. *Rheumatology (Oxford).* 2005; 44:366–371. (Published erratum appears in *Rheumatology [Oxford]* 2005, 44:569.). [PubMed: 15561735]
36. Iannone F, Riccardi MT, Guiducci S, et al. Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension. *Ann Rheum Dis.* 2008; 67:1121–1126. [PubMed: 18029384]
37. Abraham DJ, Vancheeswaran R, Dashwood MR, et al. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. *Am J Pathol.* 1997; 151:831–841. [PubMed: 9284832]

38. Morelli S, Ferri C, Di Francesco L, et al. Plasma endothelin-1 levels in patients with systemic sclerosis: influence of pulmonary or systemic arterial hypertension. *Ann Rheum Dis.* 1995; 54:730–734. [PubMed: 7495344]
39. Shi-Wen X, Renzoni EA, Kennedy L, et al. Endogenous endothelin-1 signaling contributes to type I collagen and CCN2 overexpression in fibrotic fibroblasts. *Matrix Biol.* 2007; 26:625–632. [PubMed: 17681742]
40. Stratton RJ, Coghlan JG, Pearson JD, et al. Different patterns of endothelial cell activation in renal and pulmonary vascular disease in scleroderma. *QJM.* 1998; 91:561–566. [PubMed: 9893759]
- 41•. Mulligan-Kehoe MJ, Drinane MC, Mollmark J, et al. Antiangiogenic plasma activity in patients with systemic sclerosis. *Arthritis Rheum.* 2007; 56:3448–3458. In this article, the authors demonstrate that plasma from scleroderma patients is angiostatic in in vitro models of angiogenesis. Angiostatin appears to be at least partially responsible for this abnormality and levels of this molecule are noted to be elevated in scleroderma plasma. [PubMed: 17907150]
42. Distler O, Del Rosso A, Giacomelli R, et al. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. *Arthritis Res.* 2002; 4:R11. [PubMed: 12453314]
43. Hummers LK, Hall A, Wigley FM, Simons M. Abnormalities in the regulators of angiogenesis in patients with scleroderma. *J Rheumatol.* 2009; 36:576–582. [PubMed: 19228661]
44. Distler O, Distler JH, Scheid A, et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. *Circ Res.* 2004; 95:109–116. [PubMed: 15178641]
45. Hebbbar M, Peyrat JP, Hornez L, et al. Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. *Arthritis Rheum.* 2000; 43:889–893. [PubMed: 10765935]
- 46••. Wipff J, Avouac J, Borderie D, et al. Disturbed angiogenesis in systemic sclerosis: high levels of soluble endoglin. *Rheumatology (Oxford).* 2008; 47:972–975. Soluble endoglin is notable for having predictive capability in other disease states. In this study, the authors show that soluble endoglin strikingly correates with a particular phenotype in scleroderma that associates with vascular disease (centromere antibody, digital ulcers, low DLCO), making this a very exciting biomarker candidate. [PubMed: 18477643]
47. Hummers, LK.; Simons, M.; Wigley, FM.; Mulligan-Kehoe, MJ. Circulating inhibitors of angiogenesis in scleroderma. Presented at the 73rd Annual Scientific Meeting of the American College of Rheumatology; Philadelphia, PA. October 16–21, 2009;
48. Wang A, Rana S, Karumanchi SA. Preeclampsia: the role of angiogenic factors in its pathogenesis. *Physiology (Bethesda).* 2009; 24:147–158. [PubMed: 19509125]